Evidence map›Paper›PMID 40868170›Full record

ArticleBiomedicines2025

Efficacy and Safety of the Combination of Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: A Real-World Retrospective Cohort Study.

Eishin Kurihara, Satoru Kakizaki, Masashi Ijima, Takeshi Hatanaka, Norio Kubo, Yuhei Suzuki, Hidetoshi Yasuoka, Takashi Hoshino, Atsushi Naganuma, Noriyuki Tani and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eishin KuriharaDepartment of Gastroenterology, SUBARU Ota Memorial Hospital, Ota 3738585, Gunma, Japan.
Satoru KakizakiDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki 3700829, Gunma, Japan.ORCID 0000-0003-0224-7093
Masashi IjimaDepartment of Gastroenterology, SUBARU Ota Memorial Hospital, Ota 3738585, Gunma, Japan.
Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 3710821, Gunma, Japan.ORCID 0000-0003-3656-285X
Norio KuboDepartment of Surgery, Gunma Saiseikai Maebashi Hospital, Maebashi 3710821, Gunma, Japan.ORCID 0000-0003-2624-2529
Yuhei SuzukiDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki 3700829, Gunma, Japan.
Hidetoshi YasuokaDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki 3700829, Gunma, Japan.
Takashi HoshinoDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki 3700829, Gunma, Japan.
Atsushi NaganumaDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki 3700829, Gunma, Japan.ORCID 0000-0003-0663-0102
Noriyuki TaniDepartment of Surgery, SUBARU Ota Memorial Hospital, Ota 3738585, Gunma, Japan.ORCID 0009-0008-8922-994X
Yuichi YamazakiDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 3718511, Gunma, Japan.ORCID 0000-0002-8633-2983
Toshio UraokaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 3718511, Gunma, Japan.ORCID 0000-0002-4425-4331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced biliary tract cancercisplatindurvalumabgemcitabinereal-world data

Identifiers

PMID40868170
PMCPMC12384017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.